Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion ...

Matthew Caufield, an analyst from H.C. Wainwright, initiated coverage of Akebia Therapeutics, Inc. (NASDAQ:AKBA) with a Buy ...

Halia Therapeutics has completed the enrolment in its Phase IIa trial of HT-6184 (Ofirnoflast) in those with lower-risk MDS.

Updated, longer-term results from the COMMANDS trial show a promising trend toward improved overall survival with ...

The global sales of anemia treatment are estimated to be worth USD 12,287.3 million in 2025 and are anticipated to reach a value of USD 23,903.5 million by 2035. Sales are projected to rise at a CAGR ...

Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering therapies inspired by genetic resilience, today ...

† Department of Chemistry, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, California 92037, United States ‡ Genomics Institute of the Novartis Research Foundation, 10675 John ...

Panelists discuss how differentiating primary from secondary erythrocytosis is crucial in guiding treatment strategies, emphasizing the importance of addressing underlying causes such as chronic ...